3 February 2012 - US Medivation Inc (NASDAQ:MDVN) and Japanese Astellas Pharma Inc (TYO:4503) unveiled earlier this week encouraging data on all efficacy endpoints from the Phase III AFFIRM study of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy.

The companies noted that men taking MDV3100 lived for a median of 18.4 months, compared with 13.6 months for men taking placebo (p < 0.0001; HR=0.631).

MDV3100 surpassed the study's team expectations in the AFFIRM trial by meeting the primary and secondary endpoints with strong statistical significance and demonstrating a favourable safety profile, said Dr Howard Scher, chief, Genitourinary Oncology Service at Memorial-Sloan Kettering Cancer Center, and the co-principal investigator of the AFFIRM trial.